Kriya Therapeutics IPO

Kriya Therapeutics has not announced IPO plans and remains a private biotechnology company focused on advancing its gene therapy pipeline through clinical trials. The company raised $112 million in Series B funding in 2022 to support its clinical development programs. Kriya has multiple programs in development, including treatments for diabetic retinopathy and other chronic conditions. As a clinical-stage biotech company, Kriya would typically need to show significant clinical progress and potentially approach commercialization before considering an IPO. The gene therapy sector has seen both successes and challenges in public markets, with investor interest varying based on clinical data and regulatory progress. There are no confirmed details about the company's IPO timeline, and it likely remains focused on executing its clinical development strategy.